MedTrace Logo

Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis

NCT04475081 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-11-26

Study results available
· View outcomes & findings →

Summary

The objective of this randomized clinical trial is to test whether administration of live attenuated MMR vaccine (measles mumps rubella; Merck) to eligible adults at highest risk for contracting COVID-19 (healthcare workers, first responders), can induce non-specific trained innate immune leukocytes that can prevent/dampen pathological inflammation and sepsis associated with COVID-19-infection, if exposed.

Conditions

  • Sepsis Syndrome

Interventions

BIOLOGICAL

MMR vaccine

Merck MMR-II vaccine

Sponsors & Collaborators

  • Parsemus Foundation

    collaborator UNKNOWN

  • Louisiana State University Health Sciences Center in New Orleans

    lead OTHER

Principal Investigators

  • Paul L Fidel, PhD · Louisiana State University Health Sciences Center - New Orleans

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-22
Primary Completion
2022-05-15
Completion
2022-05-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04475081 on ClinicalTrials.gov